At Neurovations Research, safety is our top concern during COVID-19.
This brief message details how we keep patients and staff safe.
Please call us with any questions or concerns. We hope to see you soon.

Woman and her Doco

Neurovations Knee Pain Study

We are currently enrolling patients in a new clinical study for moderate to severe knee pain to evaluate a very unique injection treatment. In this study, a tiny amount of DNA is placed in the knee, which may help your joint produce its own powerful, anti-inflammatory medication.

If you have moderate to severe knee pain from osteoarthritis, please reach out to us in Napa at Neurovations Research. We are the region’s most experienced clinical research facility for chronic pain.

If accepted for this study, you will receive free study-related medical care and be compensated for your travel time and expenses. To see if you qualify, call Neurovations Research at 707-252-9606 or click on the link below to email us.

Neurovations Lumbar

Disc Herniation Study

We are enrolling patients in a new clinical study for lumbar disc herniation to evaluate a very unique injection treatment. In this study, a tiny amount of an enzyme is placed in the herniated disc, which may help reduce symptoms associated with lumbar disc herniation.

If you have inadequate pain relief from simpler treatments for a lumbar disc herniation, please reach out to us in Napa at Neurovations Research. We are the region’s most experienced clinical research facility for pain.

If accepted for this study, you will receive free study-related medical care. To see if you qualify, call Neurovations at 707-252-9606 or click on the link below to email us.

Research and Partnerships

Neurovations Research, founded in 2010, is at the forefront of innovation in the field of pain and neuromodulation. CEO and founder Dr. Eric Grigsby has led clinical trials with more than fifty companies, partnering with industry leaders and early-stage companies in medical device (Phase I-IV) and pharmaceutical trials (Phase II-IV), including first-in-man medical device trials, double-blinded and placebo-controlled trials.

Our patient-centered approach creates success in rapid enrollment and quality trial management. Our investigator training facility helps us provide an unparalleled synergy of clinical research capabilities for pain management and neuroscience trials. We can provide site assessment and site qualifications services and we bring hands-on peer-to-peer mentoring to our investigators.

Xalud,  located in Berkeley, California, has partnered with Neurovations for almost a decade. Xalud Therapeutics, Inc. is developing novel therapies for the treatment of neuro-inflammatory diseases. Xalud is also developing treatments for inflammatory joint disorders including osteoarthritis and rheumatoid arthritis.

Research was completed in partnership with Bioness to study the use of peripheral nerve stimulation that eventually led to FDA approval. Bioness is the leading provider of innovative technologies helping people regain mobility and independence. Bioness solutions include implantable and external neuromodulation systems, robotic systems, and software-based therapy programs providing functional and therapeutic benefits for individuals affected by pain, central nervous system disorders, and orthopedic injuries.

Neurovations founder Dr. Grigsby developed the early technology for spinal electrode delivery for treatment of pain, which later became a component for therapeutic treatment with Abbott. Abbott invents, develops and delivers a diverse range of essential healthcare solutions that support disease prevention, diagnosis and treatment.